After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
The combined company's MALT1 inhibitor has started phase 1.
Crunch time approaches for UroGen.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
Herthena-Lung02 data are an ASCO shocker.
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
